Deep Track Capital LP Grows Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Deep Track Capital LP increased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 0.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,836,282 shares of the biopharmaceutical company's stock after acquiring an additional 114,822 shares during the period. Ocular Therapeutix comprises about 4.1% of Deep Track Capital LP's investment portfolio, making the stock its 8th biggest holding. Deep Track Capital LP owned 8.16% of Ocular Therapeutix worth $109,622,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Barclays PLC boosted its position in Ocular Therapeutix by 37.1% in the third quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock worth $4,451,000 after purchasing an additional 138,441 shares during the last quarter. Courier Capital LLC bought a new position in shares of Ocular Therapeutix in the 4th quarter worth approximately $482,000. RoundAngle Advisors LLC purchased a new position in shares of Ocular Therapeutix in the fourth quarter worth approximately $1,695,000. SG Americas Securities LLC grew its position in Ocular Therapeutix by 58.7% during the fourth quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company's stock valued at $612,000 after buying an additional 26,511 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Ocular Therapeutix by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock valued at $285,000 after buying an additional 3,347 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

Insider Transactions at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,475 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the sale, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OCUL. William Blair initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating on the stock. Royal Bank of Canada began coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target for the company. Needham & Company LLC reduced their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.25.

Ocular Therapeutix Stock Down 7.1 %

OCUL opened at $7.18 on Wednesday. The company has a market capitalization of $1.14 billion, a PE ratio of -5.44 and a beta of 1.51. The firm has a 50-day simple moving average of $7.42 and a two-hundred day simple moving average of $8.35. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 52 week low of $4.79 and a 52 week high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.